Sodium/glucose cotransporter

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (09:25, 13 August 2024) (edit) (undo)
 
(13 intermediate revisions not shown.)
Line 1: Line 1:
-
<StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''>
+
<StructureSection load='8hez' size='340' side='right' caption='Human glycosylated SGLT2 (cyan) complex with PDZK1-interacting protein (green), drug dapagliflozin and Na+ ion (PDB code [[8hez]])' scene='10/1042600/Cv/1'>
-
This is a default text for your page '''Sodium/glucose cotransporter'''. Click above on '''edit this page''' to modify. Be careful with the &lt; and &gt; signs.
+
-
 
+
-
 
+
== Function ==
== Function ==
-
'''Sodium/glucose cotransporter''' (SGLT) is responsible for glucose absorption across membranes. SGLT1 and SGLT2 which are expressed in different tissues, have similar active sites but differ in their non-active site structures. SGLT1 is responsible of glucose absorption in the small intestine and SGLT2 in kidney<ref>PMID:26125647</ref>.
+
'''Sodium/glucose cotransporter''' (SGLT) is responsible for glucose absorption across membranes. SGLT1 and SGLT2 which are expressed in different tissues, have similar active sites but differ in their non-active site structures. '''SGLT1''' is responsible of glucose absorption in the small intestine and '''SGLT2''' in kidney<ref>PMID:26125647</ref>.
== Disease ==
== Disease ==
Line 13: Line 10:
== Relevance ==
== Relevance ==
-
SGLT2 inhibitors aid in hypertension, acute cardiac failure, bradycardia, acute pulmonary oedema, asthma, bronchitis and COPD<ref>PMID:36819350</ref>..
+
SGLT2 inhibitors aid in hypertension, acute cardiac failure, bradycardia, acute pulmonary oedema, asthma, bronchitis and COPD<ref>PMID:36819350</ref>.
== Structural highlights ==
== Structural highlights ==
-
This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.
+
The drug Dapagliflozin contains a <scene name='10/1042600/Cv/5'>glucose moiety which stacks against residue Y290</scene> of SGLT2. The <scene name='10/1042600/Cv/6'>glucose moiety forms multiple H-bonds</scene> to SGLT2<ref>PMID:38057552</ref>. Water molecule is shown as red sphere.
 +
See also:
 +
*[[Canagliflozin]]
 +
*[[Dapagliflozin]]
 +
*[[Empagliflozin]]
==3D structures of sodium/glucose cotransporter==
==3D structures of sodium/glucose cotransporter==
-
 
+
[[Sodium/glucose cotransporter 3D structures]]
</StructureSection>
</StructureSection>

Current revision

Human glycosylated SGLT2 (cyan) complex with PDZK1-interacting protein (green), drug dapagliflozin and Na+ ion (PDB code 8hez)

Drag the structure with the mouse to rotate

References

  1. ↑ Poulsen SB, Fenton RA, Rieg T. Sodium-glucose cotransport. Curr Opin Nephrol Hypertens. 2015 Sep;24(5):463-9. PMID:26125647 doi:10.1097/MNH.0000000000000152
  2. ↑ Dominguez Rieg JA, Rieg T. What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition. Diabetes Obes Metab. 2019 Apr;21 Suppl 2(Suppl 2):43-52. PMID:31081587 doi:10.1111/dom.13630
  3. ↑ Jasleen B, Vishal GK, Sameera M, Fahad M, Brendan O, Deion S, Pemminati S. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk. Cureus. 2023 Jan 18;15(1):e33939. PMID:36819350 doi:10.7759/cureus.33939
  4. ↑ Hiraizumi M, Akashi T, Murasaki K, Kishida H, Kumanomidou T, Torimoto N, Nureki O, Miyaguchi I. Transport and inhibition mechanism of the human SGLT2-MAP17 glucose transporter. Nat Struct Mol Biol. 2024 Jan;31(1):159-169. PMID:38057552 doi:10.1038/s41594-023-01134-0

Proteopedia Page Contributors and Editors (what is this?)

Michal Harel, Alexander Berchansky, Jaime Prilusky

Retrieved from "http://52.214.119.220/wiki/index.php/Sodium/glucose_cotransporter"
Personal tools